A dynamic molecular glue targets a plastic MDA5 filament interface to stimulate innate immunity
In the authors' words
Innate immune signaling is a double-edged sword: uncontrolled activation drives autoinflammatory diseases, while controlled activation enhances antiviral and antitumor immunity. MDA5, a cytosolic dsRNA sensor that activates type I interferon signaling, mediates both immunopathology and protective immunity, yet small-molecule modulators have remained elusive. Here we report MA2, a first-in-class selective MDA5 agonist that acts as a molecular glue. MA2 binds a cryptic inter-protomer pocket within MDA5 filaments that undergoes ATPase-associated conformational remodeling. Rather than rigidly locking the interface, MA2 remains bound while accommodating and reshaping these structural transitions, strengthening MDA5-dsRNA and inter-protomer interactions and attenuating ATP hydrolysis. MA2 does not induce new filament assembly but potentiates pre-existing filaments, enabling context-dependent activation in dsRNA-enriched cells. MA2 enhances antiviral activity and synergizes with chemotherapeutic agents and natural killer cells to promote tumor cell killing. These findings establish dynamic molecular glues as a strategy for targeting conformationally plastic interfaces previously considered undruggable.
In plain words AI summary
Researchers developed MA2, the first small molecule that selectively activates MDA5, a protein that detects viral RNA and triggers immune responses. MA2 acts as a molecular glue that binds to a hidden pocket between MDA5 protein units while they change shape during normal activity. It strengthens MDA5's grip on viral RNA and its connections to other MDA5 units, slowing down ATP breakdown without freezing the structure. MA2 boosts existing MDA5 filaments rather than creating new ones, so it only activates cells that already have viral RNA present. The molecule increased antiviral activity and worked with chemotherapy and natural killer cells to kill tumor cells.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Wednesday, October 21. bioRxiv. Preprint, not yet peer-reviewed.